Dr. Reem Karmali
Claim this profileNorthwestern University
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
16 reported clinical trials
31 drugs studied
Area of expertise
1Lymphoma
Global LeaderCCND1 positive
t(11;14) positive
MYC positive
2Non-Hodgkin's Lymphoma
MYC positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials Reem Karmali is currently running
Pembrolizumab + Tazemetostat
for Non-Hodgkin's Lymphoma
This phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T cell therapy for aggressive non hodgkins lymphoma. A monoclonal antibody, such as pembrolizumab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and tazemetostat may work better to treat patients who have received ASCT or CAR-T cell therapy for aggressive non hodgkins lymphoma.
Recruiting1 award Phase 2
Cell Therapy
for Non-Hodgkin's Lymphoma
This trial tests a new treatment where a patient's own immune cells are enhanced to fight difficult-to-treat lymphoma. It targets patients whose cancer hasn't responded to at least two other treatments. The modified cells aim to better recognize and attack the cancer. This new method improves the ability of the patient's immune cells to find and destroy cancer cells.
Recruiting1 award Phase 219 criteria
More about Reem Karmali
Clinical Trial Related1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Reem Karmali has experience with
- Rituximab
- Cyclophosphamide
- Nivolumab
- Lenalidomide
- Pembrolizumab
- Prednisone
Breakdown of trials Reem Karmali has run
Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Reem Karmali specialize in?
Reem Karmali focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Reem Karmali currently recruiting for clinical trials?
Yes, Reem Karmali is currently recruiting for 8 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Reem Karmali has studied deeply?
Yes, Reem Karmali has studied treatments such as Rituximab, Cyclophosphamide, Nivolumab.
What is the best way to schedule an appointment with Reem Karmali?
Apply for one of the trials that Reem Karmali is conducting.
What is the office address of Reem Karmali?
The office of Reem Karmali is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.